Two drugs tested with radiation for a newly found high-grade glioma
Original title: Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in a small number of people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing whether two drugs are safe to give before and during radiation.
Who this trial is for. This trial is for people with a newly found high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. It tests two drugs, avutometinib and defactinib, given before radiation starts. People whose tumor is MGMT unmethylated glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary take the drugs during radiation too.
Where it stands. This trial has not reported results. The team is checking if people can finish the first stage of drugs and start radiation within 6 weeks. They are also watching for side effects. They will look at scans after the first cycle of drugs. The answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone who fits this trial could ask their care team about it. The care team can help sort out if it makes sense. Whether a person can join is up to the trial team.
What it doesn't mean: This does not mean these drugs work. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.